← Back to Clinical Trials
Recruiting NCT07561567

NCT07561567 Feasibility and Effectiveness of Respiratory Movement Management in Lung Cancer Receiving Stereotactic Radiotherapy Using a Novel Positional Fixation Device

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07561567
Status Recruiting
Phase
Sponsor Tianjin Medical University Cancer Institute and Hospital
Condition Lung Cancer, Non-Small Cell
Study Type OBSERVATIONAL
Enrollment 50 participants
Start Date 2026-05-10
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Chest and abdominal compressionbreathing management

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 50 participants in total. It began in 2026-05-10 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this clinical trial is to understand the safety and effectiveness of abdominal pressure devices in inhibiting respiratory movement in lung cancer patients. The main question it aims to answer is: Did the abdominal pressure device reduce the respiratory movement of participants with lung cancer tumors? Participants will: Record how much they use abdominal pressure devices to suppress lung cancer tumor respiratory movement

Eligibility Criteria

Inclusion Criteria: Clinical diagnosis is solitary peripheral lung cancer, and after comprehensive evaluation by the participating physicians based on the patient's clinical data, it is suitable for receiving SBRT treatment; Exclusion Criteria: Central or super central lung cancer patients who are intolerant or unwilling to undergo respiratory suppression and chest and abdominal compression fixation

Contact & Investigator

Central Contact

Xuyao Yu Dr

✉ yuxuyao@tmu.edu.cn

📞 86-022-23341405

Frequently Asked Questions

Who can join the NCT07561567 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Cancer, Non-Small Cell. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07561567 currently recruiting?

Yes, NCT07561567 is actively recruiting participants. Contact the research team at yuxuyao@tmu.edu.cn for enrollment information.

Where is the NCT07561567 trial being conducted?

This trial is being conducted at Tianjin, China.

Who is sponsoring the NCT07561567 clinical trial?

NCT07561567 is sponsored by Tianjin Medical University Cancer Institute and Hospital. The trial plans to enroll 50 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology